Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Zhilan Chai"'
Autor:
Jinyang Li, Jiasheng Lu, Haiyan Guo, Jianfen Zhou, Songli Wang, Kuan Jiang, Zhilan Chai, Shengyu Yao, Xiaoyi Wang, Linwei Lu, Cao Xie, Yi Chen, Weiyue Lu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 1, Pp 283-299 (2021)
AL3810, a molecular dual inhibitor of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), has earned the permission of phase II clinical trial for tumor treatment by China FDA. As a reversible ATP-com
Externí odkaz:
https://doaj.org/article/aff71be37587480d8683d0843322f543
Autor:
Cao Xie, Jianfen Zhou, Weiyue Lu, Jiasheng Lu, Songli Wang, Jinyang Li, Zhilan Chai, Danni Ran
Publikováno v:
Journal of Controlled Release. 322:542-554
Owing to the binding capacity to ɑvβ3 integrin overexpressed on glioma, vasculogenic mimicry and neovasculature, the peptide c(RGDyK) has been exploited pervasively to functionalize nanocarriers for targeted delivery of bioactives. The former study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f85f8daeac88637fc1f72c73b2597cb8
https://doi.org/10.1016/j.jconrel.2020.04.009
https://doi.org/10.1016/j.jconrel.2020.04.009
Autor:
Cao Xie, Yu Liu, Linwei Lu, Dongli Wang, Jinyang Li, Haiyan Guo, Ruifeng Wang, Jianfen Zhou, Zhilan Chai, Weiyue Lu, Songli Wang, Shengyu Yao
Publikováno v:
Journal of Controlled Release. 320:63-72
In glioblastoma with typical immunosuppressive characteristics, immune checkpoint inhibitors treatment showed unsatisfactory clinical effects, attributable to the exclusion of antibodies by blood-brain barrier (BBB) to a large extent. Herein, a conju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a130e556de7b907f5f6580b1f9cf3ad9
https://doi.org/10.1016/j.jconrel.2020.01.005
https://doi.org/10.1016/j.jconrel.2020.01.005
Autor:
Kuan Jiang, Yanyu Zhang, Jing Wang, Zhilan Chai, Xuefeng Hu, Weiyue Lu, Cao Xie, Huitong Ruan, Liangfang Zhang, Changyou Zhan, Jinyang Li, Linwei Lu, Ronnie H. Fang, Jianfen Zhou, Danni Ran
Publikováno v:
ACS Nano. 13:5591-5601
The safe and efficient delivery of chemotherapeutic agents remains critical to anticancer therapy. Herein, we report on a targeted drug delivery system based upon a modified cell membrane coating technique and drug nanocrystals (NCs). Specifically, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e932ad86f71eb838be208e2ebb1c1893
https://doi.org/10.1021/acsnano.9b00661
https://doi.org/10.1021/acsnano.9b00661
Autor:
Jianfen Zhou, Jinyang Li, Haiyan Guo, Linwei Lu, Zhilan Chai, Cao Xie, Kuan Jiang, Xiaoyi Wang, Jiasheng Lu, Weiyue Lu, Songli Wang, Shengyu Yao, Yi Chen
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 1, Pp 283-299 (2021)
Acta Pharmaceutica Sinica B, Vol 11, Iss 1, Pp 283-299 (2021)
AL3810, a molecular dual inhibitor of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), has earned the permission of phase II clinical trial for tumor treatment by China FDA. As a reversible ATP-com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc1fb3d0d46297b4e34343467d2e7da
https://pubmed.ncbi.nlm.nih.gov/33532193
https://pubmed.ncbi.nlm.nih.gov/33532193
Autor:
Huitong Ruan, Xishan Chen, Qing Shen, Huan Wang, Weiyue Lu, Man Ying, Shengyu Yao, Bingxia Su, Zhilan Chai, Changyou Zhan, Cao Xie, Mingfei Zhang
Publikováno v:
Journal of Controlled Release. 279:306-315
The receptor associated protein (RAP) is a 39 kDa chaperone protein, binding tightly to low-density lipoprotein receptor-related protein-1 (LRP1) that is overexpressed in glioma, tumor neovasculature, vasculogenic mimicry (VM), the blood–brain barr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef99f47ef26b3d1af83fc4556b172f7a
https://doi.org/10.1016/j.jconrel.2018.04.035
https://doi.org/10.1016/j.jconrel.2018.04.035
Autor:
Hangchang Zhu, Huitong Ruan, Ruifeng Wang, Man Ying, Weiyue Lu, Songli Wang, Zhilan Chai, Mingfei Zhang, Danni Ran, Xiaoyi Wang
Publikováno v:
ACS Applied Materials & Interfaces. 10:19473-19482
The clinical treatment of aggressive glioma has been a great challenge, mainly because of the complexity of the glioma microenvironment and the existence of the blood-brain tumor barrier (BBTB)/blood-brain barrier (BBB), which severely hampers the ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba0e0b42af2d05f121e5c5308b31511d
https://doi.org/10.1021/acsami.8b05235
https://doi.org/10.1021/acsami.8b05235
Autor:
Huan Wang, Mingfei Zhang, Jun Pan, Zhilan Chai, Weiyue Lu, Changyou Zhan, Songli Wang, Linwei Lu, Man Ying, Huitong Ruan, Xiaoyi Wang
Publikováno v:
Molecular Pharmaceutics. 15:2437-2447
The robust proliferation of tumors relies on a rich neovasculature for nutrient supplies. Therefore, a basic strategy of tumor targeting therapy should include not only killing regular cancer cells but also blocking tumor neovasculature. D-peptide DA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95097299952557140fad7c9bcefdc8c3
https://doi.org/10.1021/acs.molpharmaceut.8b00270
https://doi.org/10.1021/acs.molpharmaceut.8b00270
Autor:
Liangfang Zhang, Huitong Ruan, Zhilan Chai, Changyou Zhan, Danni Ran, Ronnie H. Fang, Xuefeng Hu, Bingxia Su, Xiaoli Wei, Kuan Jiang, Linwei Lu, Weiyue Lu
Publikováno v:
Journal of Controlled Release. 264:102-111
The blood brain barrier separates the circulating blood from the extracellular fluid in the central nervous system and thus presents an essential obstacle to brain transport of therapeutics. Herein, we report on an effective brain-targeted drug deliv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e625409becd9ba06eb82ffbb3be33266
https://doi.org/10.1016/j.jconrel.2017.08.027
https://doi.org/10.1016/j.jconrel.2017.08.027
Autor:
Jinyang, Li, Zhilan, Chai, Jiasheng, Lu, Cao, Xie, Danni, Ran, Songli, Wang, Jianfen, Zhou, Weiyue, Lu
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 322
Owing to the binding capacity to ɑ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3fd9264fbfe94dd6d02c2b65295299ae
https://pubmed.ncbi.nlm.nih.gov/32277962
https://pubmed.ncbi.nlm.nih.gov/32277962